Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
The preliminary amendment dated 16 May 2025, in which claims 4, 28-30, 37, 38, 52, 61-63 have been amended, and claims 2-3, 5-27, 31-36, 39-51, 53-60, 64-67 have been cancelled, is acknowledged.
Claims 1, 4, 28-30, 37-38, 52, 61-63 are pending in the instant application.
Claims 1, 4, 28-30, 37-38, 52, 61-63 are examined herein.
Priority
The instant application is a Continuation of International Application No. PCT/US2023/021846, filed on 11 May 2023, which claims priority from U.S. Provisional Patent Application No. 63/341,068, filed on 12 May 2022.
Information Disclosure Statement
The information disclosure statement (IDS) submitted on 8 July 2025 is acknowledged and considered.
Claim objection
Claim 52 is objected to because the text “wherein the compound has the structure: […], […], or […].” could read --wherein the compound is selected from: […], […], and […]. –
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 30, 38, 52 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claim 30 is drawn to the compound of claim 1 [….] having a structure of Formula Ic-1
PNG
media_image1.png
152
292
media_image1.png
Greyscale
. Yet claim 1 does not recite diastereoisomers or enantiomers of a compound of formula I. As such, there is insufficient antecedent basis for Formula Ic-1 of claim 30, in claim 1.
The same analysis applies to claim 38, and to claim 52.
Appropriate correction/clarification is required.
Claims 1, 61-63 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claim 1 is drawn to a compound of formula (I)
PNG
media_image2.png
146
274
media_image2.png
Greyscale
where R4 is, for example, H, and p is, for example, 0. This is confusing because the default substituent is hydrogen.
Appropriate clarification is required.
Claims 1, 4, 28-30, 61-63 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claim 1 is drawn to a compound of formula (I)
PNG
media_image2.png
146
274
media_image2.png
Greyscale
where
PNG
media_image3.png
92
598
media_image3.png
Greyscale
.
It is noted that R2x and R2y are, for example, H, or C1-6 alkyl.
It is also noted that R2a is present in the following groups as part of R2:
PNG
media_image4.png
114
564
media_image4.png
Greyscale
.
It appears that claim 1 recites that R2a and R2x (or R2y), combined with the atoms they are attached to, form a 4 to 6 membered heterocycloalkyl; based on the definitions of R2a, it seems that such a heterocycloalkyl contains N, or -O-CO-N-, or -SO2-N-, or -SO-NH-N- as part of the heterocycloalkyl ring, with substituents as defined by R2. It is unclear what is meant by “having 0 to 2 additional heteroatoms each independently N, O or S, substituted with 0 to 3 C1-6 alkyl”, given that the substituents on the heterocycloalkyl ring formed are already defined by R2a and R2.
Appropriate clarification is required.
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL--The specification shall contain a written description of theinvention, and of the manner and process of making and using it, in such full, clear, concise,and exact terms as to enable any person skilled in the art to which it pertains, or with which itis most nearly connected, to make and use the same, and shall set forth the best modecontemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of themanner and process of making and using it, in such full, clear, concise, and exact terms as toenable any person skilled in the art to which it pertains, or with which it is most nearlyconnected, to make and use the same, and shall set forth the best mode contemplated by theinventor of carrying out his invention.
Claim 63 is rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for a method of inhibiting LRRK2 in a cell with a compound of formula (I),
does not reasonably provide enablement for the claimed treatment of a LRRK2-associated disease or condition with a compound of formula (I), as recited by claim 63. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims.
The factors to be considered in determining whether a disclosure meets the enablement requirements of 35 U.S.C. 112, first paragraph, have been described in In re Wands, 858 F.2d 731, 8 USPQ2d 1400 (Fed. Cir.1988). The court in Wands states, “Enablement is not precluded by the necessity for some experimentation, such as routine screening. However, experimentation needed to practice the invention must not be undue experimentation. The key word is ‘undue’, not experimentation’” (Wands, 8 USPQ2sd 1404). Clearly, enablement of a claimed invention cannot be predicated on the basis of quantity of experimentation required to make or use the invention. “Whether undue experimentation is needed is not a single, simple factual determination, but rather is a conclusion reached by weighing many factual considerations” (Wands, 8 USPQ2d 1404). Among these factors are: (1) the nature of the invention; (2) the breath of the claims; (3) the state of the prior art; (4) the predictability or unpredictability of the art; (5) the relative skill of those in the art; (6) the amount of direction or guidance presented; (7) the presence or absence of working examples; and (8) the quantity of experimentation necessary.
While all of these factors are considered, a sufficient amount for a prima facie case is discussed below.
(1) The nature of the invention and (2) the breadth of the claims:
Claim 63 is drawn to a method of treating a LRRK2-associated disease, said method comprising administering to a subject in need thereof an 3effective amount of a compound of formula (I).
Thus, claim 63, taken together with the specification, implies that a compound of instant formula (I) can treat any LRRK2-associated disease in a subject in need thereof.
The claims are far broader than the disclosure.
(3) The state of the prior art and (4) the predictability or unpredictability of the art:
The genus of LRRK2-2associated diseases to be treated encompasses a very large number of diseases; each disease has different symptoms, different etiology, different mechanism and different treatment.
Wallings et al. (Biochemical Society Transactions 2019, 47, 1581-1595, cited in PTO-892) teach (Abstract) that mutations in the leucine-rich-repeat kinase 2 (LRRK2) gene are associated with familial and sporadic cases of Parkinson’s disease but are also found in immune-related disorders such as inflammatory bowel disease, tuberculosis and leprosy. LRRK2 is highly expressed in immune cells and has been functionally linked to pathways pertinent to immune cell function, such as cytokine release, autophagy and phagocytosis.
Wallings teaches (page 1582) that the increased kinase activity of LRRK2 mutants has been linked to the pathological function of LRRK2 in disease. However, when considering different diseases, cell types, and mutations, the role of LRRK2 kinase activity may not be quite as simple as originally thought (Table 1).
Wallings teaches (page 1584, first paragraph) that leprosy is a LRRK2-associated disease. However, results evaluating the association of LRRK2 variants with leprosy susceptibility have been inconsistent.
Wallings further teaches (page 1584, third paragraph) that LRRK2 in tuberculosis and other bacterial infections LRRK2 has been implicated in several bacterial infections. There are contrasting reports between the effects of kinase inhibition on different bacterial infections, with LRRK2 kinase inhibition enhancing the restriction of some bacteria or increasing susceptibility to infection for others.
Wallings teaches (page 1584, last paragraph, page 1585, first two paragraphs) that, with regards to LRRK2, genetic variances and mutations in the LRRK2 gene have been demonstrated to increase the risk of developing PD in both CD (Crohn’s disease) and UC (ulcerative colitis) patients. The role of LRRK2 kinase activity in IBD is still unclear. The down-regulation of LRRK2 was previously shown to enhance the susceptibility to dextran sulfate sodium salt (DSS)-induced colitis, suggesting a loss of LRRK2 activity may increase the risk for inflammation in the gut. However, in a mouse model of DSS-induced colitis, overexpression of the Lrrk2 gene causes increased severity in colitis, which was ameliorated with LRRK2 kinase inhibitors. From this data, it is still not clear if the role of LRRK2 in IBD is due to a loss- or gain-of-function.
Wallings teaches the role of LRRK2 in autophagy (Table 2), and teaches (page 1590) that LRRK2 could control different cellular pathways (or modulate the same pathway differentially) based on the expression of LRRK2 activators and partners and the complexes formed in a cell-type-specific manner. Wallings teaches that despite the crucial role autophagy and the lysosome play in regulating different aspects of the innate and adaptive immune systems, mechanistic insight into how LRRK2’s role in autophagy and lysosome function impacts inflammatory pathways in immune cells remains unknown, and is an important area for further research.
Wallings teaches (page 1590, under Concluding remarks) that additional research is required in order to establish the involvement of LRRK2 in inflammatory pathways in different immune cell types. Specifically, further research is required to unveil the cell-type dependent manner in which LRRK2 kinase activity regulates these different cellular pathways. LRRK2 kinase inhibitors have been discussed for their potential therapeutic effects in diseases such as PD where aberrant LRRK2 kinase activity is apparent. However, a loss of LRRK2 kinase activity may lead to an increased risk of infection and inflammation in the periphery. Therefore, such malignant side effects would need to be taken into consideration if such inhibitors were to be therapeutically beneficial.
Wallings teaches (page 1590-1591) that a large percentage of the research aiming to understand LRRK2 enzymatic function has focused on its kinase activity. However, there is still uncertainty about the contribution of GTPase activity to cellular toxicity in immune cells. Although many model organisms with interesting phenotypes have been developed based upon familial mutations in the GTPase domain of LRRK2, mechanistic insight into the contribution of GTPase activity is so far lacking.
Wallings teaches that the enzymatic core of LRRK2 is surrounded by protein–protein interaction domains. The G2385R mutation, which is located in the WD40 domain of LRRK2, is a risk factor for PD.
Wallings teaches (page 1591) that there are discrepancies in the literature highlighting cell-type dependent effects of LRRK2 on immune cell function. Future research will benefit from a direct comparison between immune cells and identifying bona fide substrates of LRRK2 in different cell types and under different immune conditions.
Thus, based on the teachings of Wallings, more research is needed in order to better understand the complexity of mechanisms in LRRK2-associated diseases and to develop treatment/ therapeutic approaches for said diseases.
Further, in view of the varying mechanisms of the different LRRK2-associated diseases, a skilled artisan would view that it is unlikely that the claimed method would be useful for treating the full scope of LRRK2-associated diseases encompassed by instant claim 63. Furthermore, as the etiology of the different LRRK2-associated diseases differs from one condition to another, it is unlikely that a skilled artisan would view that the instantly claimed method comprising administering a compound of formula (I) of the instant application, could be used to treat the full scope of LRRK2-associated diseases, as in claim 63.
Karami et al. (Journal of Translational Medicine 2025, 23, 754, cited in PTO-892) teach recent advances in targeting LRRK2 for Parkinson’s disease treatment. Karami reviews LRRK2 gene in sporadic Parkinson’s disease, or in idiopathic PD, the LRRK2 pathologies, as well as the role of LRRK2 in the immune system. Importantly, Karami teaches (page 12 of 25) the need to evaluate small organic molecules LRRK2 inhibitors in relevant animal models of disease, in order to establish efficacy in treating disease.
Further, Karami teaches that LRRK2 is not only expressed in the brain; it can also be expressed in the kidneys, the lungs, and the immune cells. So, the safety of LRRK2-targeted drugs should be investigated in preclinical and clinical trials. Karami teaches (page 12 of 25, right column, last two paragraphs) that LRRK2 knock-out rats and mice showed adverse effects in the kidneys and lungs.
In is noted that, as of May 2026, BIIB122 (DNL151), an investigational small molecule inhibitor of LRRK2 (leucine-rich repeat kinase 2), did not slow the progression of Parkinson’s disease versus placebo, in phase 2b clinical trials. A Phase 2a study evaluating the small molecule inhibitor in carriers of a pathogenic LRRK2 variant is planned (Biogen Press Release, May 21, 2026, Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease, cited in PTO-892).
(5) The relative skill of those in the art:
The level of skill in the art is that of the authors of the references cited to support the examiner’s position (MDs, PhDs, or those with advanced degrees and the requisite experience in drug discovery research).
(6) The amount of direction or guidance presented and (7) the presence or absence of working examples:
A disclosure should contain representative examples which provide reasonable assurance to one skilled in the art that the compounds of formula (I) are effective in treating any LRRK2- 2associated disease.
The specification has provided guidance for the LRRK2 inhibitory activity of the compounds of the invention in an in vitro assay (Table 8).
No compound of instant formula (I) has been evaluated in any animal model of disease.
As such, the specification does not provide any data regarding the ability of the compounds of the invention to treat any LRRK2- 2associated disease.
(8) The quantity of experimentation necessary:
Considering the state of the art and the high unpredictability in the art, the breadth of the claims, and the lack of guidance provided in the specification, one of ordinary skill in the art would be burdened with undue experimentation to practice the invention commensurate in scope with instant claim 63.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
(a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention.
Claim 1 is rejected under 35 U.S.C. 102(a)(1) and 102(a)(2) as being anticipated by Zhang et al. (US 2021/0317118, cited in PTO-892).
Zhang (US 2021/0317118) teaches (page 19, [0294], last compound, left column) the following compound:
PNG
media_image5.png
120
202
media_image5.png
Greyscale
, which is a compound of formula I of instant claim 1
PNG
media_image6.png
146
282
media_image6.png
Greyscale
for which the following definitions apply:
ring A is a C4-cycloalkyl; m = p = 0; R3 = Br (halogen); R2x = R2y = R2y = H; n = 1;
R2 is -N(R2a)C(O)OR2b, wherein R2a = H, R2b = t-Bu (C4 alkyl).
Zhang also teaches (page 19, [0294], second compound, right column) the following compound:
PNG
media_image7.png
108
176
media_image7.png
Greyscale
, which is a compound of formula I of instant claim 1
PNG
media_image6.png
146
282
media_image6.png
Greyscale
for which the following definitions apply:
ring A is a C4-cycloalkyl; m = 0;
R4 is -N(R3a)(R3b), where R3a = R3b = H; p = 1;
R3 = Br (halogen);
R2x = R2y = R2y = H; n = 1;
R2 is -N(R2a)C(O)OR2b, wherein R2a = H, R2b = t-Bu (C4 alkyl).
As such, a compound of instant claim 1 is anticipated by Zhang.
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
Claims 1, 4, 61, 63 are rejected under 35 U.S.C. 103 as being unpatentable over Hurley et al. (WO 2013/007768, cited in PTO-892), in view of Galatsis et al. (US 2017/0073343, cited in PTO-892).
Hurley (WO 2013/007768) teaches (claim 16, pages 177-178) the following compounds:
PNG
media_image8.png
156
200
media_image8.png
Greyscale
PNG
media_image9.png
164
182
media_image9.png
Greyscale
PNG
media_image10.png
176
208
media_image10.png
Greyscale
which are direct homologs -CH2-CN vs. -CN of compounds of formula I of instant claim 1
PNG
media_image6.png
146
282
media_image6.png
Greyscale
for which the following definitions apply:
ring A is a C6-cycloalkyl; m = 1; R1 = -CN;
p = 0; R3 = H;
R2x = R2y = H; n = 0;
R2 is -N(R2a)SO2R2b, wherein R2a = H, R2b = methyl (C1 alkyl) (first compound above); or
R2 is - N(R2a)( R2b) where R2a = H = R2b (second compound above); or
R2 is -N(R2a)C(O)OR2b, wherein R2a = H, R2b = methyl (C1 alkyl) (third compound above).
The compounds above disclosed by Hurley are also direct homologs -CH2-CN vs. -CN of compounds of formula (Ia) of instant claim 4
PNG
media_image11.png
146
284
media_image11.png
Greyscale
, for which the following definitions apply:
ring A is a C6-cycloalkyl; m = 1; R1 = -CN;
R4 = H; R3 = H;
R2x = R2y = H; n = 0;
R2 is -N(R2a)SO2R2b, wherein R2a = H, R2b = methyl (C1 alkyl) (first compound above); or
R2 is - N(R2a)( R2b) where R2a = H = R2b (second compound above); or
R2 is -N(R2a)C(O)OR2b, wherein R2a = H, R2b = methyl (C1 alkyl) (third compound above).
Hurley also teaches (page 3, lines 4-5) pharmaceutical compositions, as in instant claim 61, comprising the compounds of the invention and a pharmaceutical excipient.
Hurley teaches (page 98, lines 5-6) that the compounds of the invention are effective to treat, for example, Alzheimer’s disease, or Parkinson’s disease, which are diseases associated with LRRK2 of instant claim 63, as taught by Galatsis (Abstract).
It would have been obvious to a person of ordinary skill in the art to synthesize a direct structural homolog -CN vs. -CH2-CN of the compounds above disclosed by Hurley, with a reasonable expectation that the resulting homologs retain therapeutic effect, namely efficacy in treating Alzheimer’s disease, or Parkinson’s disease, of the compounds taught by Hurley.
In the absence of unexpected results, stereoisomers are considered obvious variants of each other. "Compounds which are position isomers (compounds having the same radicals in physically different positions on the same nucleus) or homologs (compounds differing regularly by the successive addition of the same chemical group, e.g., by -CH2- groups) are generally of sufficiently close structural similarity that there is a presumed expectation that such compounds possess similar properties". In re Wilder, 563 F.2d 457, 195 USPQ 426 (CCPA 1977).
As such, claims 1, 4, 61, 63 are rejected as prima facie obvious.
Claims 1, 4, 61, 63 are rejected under 35 U.S.C. 103 as being unpatentable over Hurley et al. (WO 2013/007768, cited in PTO-892), in view of Galatsis et al. (US 2017/0073343, cited in PTO-892).
Hurley (WO 2013/007768) teaches broadly ([0052], page 16, also claim 19) the following compounds of formula I,
PNG
media_image12.png
126
198
media_image12.png
Greyscale
where
X is CH (page 65, line 19);
Y is CR5 (page 65, line 19), where R5 is, for example,
PNG
media_image13.png
76
362
media_image13.png
Greyscale
PNG
media_image14.png
102
588
media_image14.png
Greyscale
and wherein -R1-R2-R3 taken together is, for example (pages 66-80):
PNG
media_image15.png
110
98
media_image15.png
Greyscale
PNG
media_image16.png
78
86
media_image16.png
Greyscale
(page 76, last line)
PNG
media_image17.png
88
60
media_image17.png
Greyscale
PNG
media_image18.png
60
60
media_image18.png
Greyscale
PNG
media_image19.png
74
152
media_image19.png
Greyscale
PNG
media_image20.png
80
104
media_image20.png
Greyscale
PNG
media_image21.png
76
82
media_image21.png
Greyscale
PNG
media_image22.png
78
70
media_image22.png
Greyscale
PNG
media_image23.png
88
76
media_image23.png
Greyscale
PNG
media_image24.png
72
96
media_image24.png
Greyscale
PNG
media_image25.png
84
78
media_image25.png
Greyscale
PNG
media_image26.png
68
74
media_image26.png
Greyscale
PNG
media_image27.png
84
80
media_image27.png
Greyscale
PNG
media_image28.png
98
78
media_image28.png
Greyscale
PNG
media_image29.png
84
108
media_image29.png
Greyscale
PNG
media_image30.png
80
68
media_image30.png
Greyscale
PNG
media_image31.png
86
96
media_image31.png
Greyscale
PNG
media_image32.png
56
56
media_image32.png
Greyscale
PNG
media_image33.png
96
180
media_image33.png
Greyscale
PNG
media_image34.png
106
44
media_image34.png
Greyscale
PNG
media_image35.png
94
78
media_image35.png
Greyscale
PNG
media_image36.png
78
138
media_image36.png
Greyscale
PNG
media_image37.png
76
132
media_image37.png
Greyscale
PNG
media_image38.png
80
58
media_image38.png
Greyscale
PNG
media_image39.png
88
76
media_image39.png
Greyscale
.
The genus above disclosed by Hurley overlaps with the instant compounds of formula I
PNG
media_image11.png
146
284
media_image11.png
Greyscale
, for which the following definitions apply:
ring A is a C3-6-cycloalkyl; or a 4 to 6-membered heterocycloalkyl having 1 heteroatom selected from N, O and S; unsubstituted (m = 0), or substituted (m = 1) with R1 = -CN, alkyl, or =O;
R4 = H; R3 = H;
R2x = R2y = R2z = H; n = 0, or 1;
R2 is -N(R2a)SO2R2b, wherein R2a = H, R2b = methyl (C1 alkyl), or cyclopropyl (C3 cycloalkyl); or
R2 is -N(R2a)C(O)OR2b, wherein R2a = H, R2b = methyl or ethyl (C1-2 alkyl); or
R2 is -N(R2a)C(O)R2b, wherein R2a = H, R2b = methyl or t-butyl, or cyclobutyl, or methoxymethyl (C1 alkyl, C4 alkyl, C4 cycloalkyl, or C2-6 alkoxyalkyl).
Hurley also teaches (page 76, last line) that -R1-R2-R3 taken together is, for example,
PNG
media_image40.png
124
442
media_image40.png
Greyscale
.
Hurley exemplifies (page 81, lines 3-5) the following compounds:
PNG
media_image8.png
156
200
media_image8.png
Greyscale
PNG
media_image9.png
164
182
media_image9.png
Greyscale
PNG
media_image10.png
176
208
media_image10.png
Greyscale
.
Hurley also discloses (pages 88, 89) the following compounds:
PNG
media_image41.png
138
130
media_image41.png
Greyscale
PNG
media_image42.png
134
118
media_image42.png
Greyscale
PNG
media_image43.png
138
118
media_image43.png
Greyscale
, where substituent R is not specifically disclosed, yet it corresponds to H, =O, -CN, -CH2-CN, or -CH2-CH2-CN, based on the list of
-R1-R2-R3 disclosed on pages 66-80.
Hurley also teaches (page 3, lines 4-5) pharmaceutical compositions, as in instant claim 61, comprising the compounds of the invention and a pharmaceutical excipient.
Hurley teaches (page 98, lines 5-6) that the compounds of the invention are effective to treat, for example, Alzheimer’s disease, or Parkinson’s disease.
Hurley does not teach a method of treating a disease associated with LRRK2 with the compounds above, as in instant claim 63.
Galatsis teaches (Abstract) that Alzheimer’s disease, or Parkinson’s disease are diseases associated with LRRK2, as in instant claim 63.
It would have been obvious to a person of ordinary skill in the art to combine the teachings of Hurley and Galatsis to arrive at the instant invention. The person of ordinary skill in the art would have synthesized a compound from the genus taught by Hurley, as described above, with a reasonable expectation that such a compound is effective to treat Alzheimer’s disease, or Parkinson’s disease.
The person of ordinary skill in the art would have replaced substituent
PNG
media_image44.png
82
108
media_image44.png
Greyscale
in any of the three specific compounds taught by Hurley
PNG
media_image45.png
202
602
media_image45.png
Greyscale
, with
PNG
media_image46.png
118
102
media_image46.png
Greyscale
or with any other substituent -R1-R2-R3 disclosed by Hurley
PNG
media_image47.png
586
648
media_image47.png
Greyscale
, with a reasonable expectation that the resulting compound retains therapeutic effect, namely is effective to treat Alzheimer’s disease, or Parkinson’s disease, which are LRRK2 associated diseases.
As such, claims 1, 4, 61, 63 are rejected as prima facie obvious.
Claims 1, 4, 28, 29, 30, 61-63 are rejected under 35 U.S.C. 103 as being unpatentable over Chappie et al. (WO2018/163030, cited in IDS).
Chappie teaches (page 5) broadly the following compounds as LRRK2 inhibitors
PNG
media_image48.png
206
326
media_image48.png
Greyscale
, where
R3 is, for example, -CN, or halogen, or C1-3 alkyl optionally substituted with halogen;
R2 is, for example, 6-membered heterocycloalkyl containing a heteroatom which is oxygen, the heterocycloalkyl being optionally substituted with, for example, C1-3 alkyl;
R1 is, for example, a 4 to 6-membered heterocycloalkyl which contains 1 to 2 heteroatoms each independently selected from N, O or S, wherein the 4 to 6-membered heterocycloalkyl is optionally substituted with 1 to 4 R8 which is, for example, C1-C3 alkyl.
Chappie teaches that the compounds of the invention and pharmaceutical compositions thereof, as in instant claim 61, are effective to inhibit LRRK2 in a cell, as in instant claim 62, and effective to treat a LRRK2-associated disease, as in instant claim 63.
Chappie teaches (page 39) the following compound
PNG
media_image49.png
170
138
media_image49.png
Greyscale
.
Chappie specifically teaches (example 16) the following compound:
PNG
media_image50.png
148
160
media_image50.png
Greyscale
, which is a compound 4.8 in which R1 is
PNG
media_image51.png
52
64
media_image51.png
Greyscale
; and
wherein substituent R3 in Chappie corresponds to R4 = -CN in instant claims 1, 4, 28;
substituent R2 in Chappie corresponds to ring A being a 6-membered heterocycloalkyl having O as ring heteroatom, substituted (m= 1) with R1 = C1 alkyl, in a compound of instant claims 1, 4, 28;
and where substituents R3 and R2 in Chappie are the same as in Formula Ic of instant claim 29, and the stereochemistry of substituent R2, namely (2R,4R)-2-methyltetrahydropyran-4-yl, is the same
PNG
media_image52.png
146
238
media_image52.png
Greyscale
as in instant claim 30.
Chappie also exemplifies other R1s, namely
PNG
media_image53.png
70
76
media_image53.png
Greyscale
(Example 7),
PNG
media_image54.png
56
46
media_image54.png
Greyscale
(Example 9),
PNG
media_image55.png
74
62
media_image55.png
Greyscale
(Example 10),
PNG
media_image56.png
50
42
media_image56.png
Greyscale
(Example 12).
Chappie does not exemplify a compound 4.8 above where R1 is a 4 to 6-membered heterocycloalkyl which contains 1 heteroatom which is N, wherein the 4 to 6-membered heterocycloalkyl is optionally substituted with C1-C3 alkyl.
It would have been obvious to a person of ordinary skill in the art to use the teachings of Chappie to arrive at the instant invention. The person of ordinary skill in the art would have synthesized a compound from the genus of compound 4.8 taught by Chappie, where R1 is a 4 to 6-membered heterocycloalkyl which contains 1 heteroatom which is N, wherein the 4 to 6-membered heterocycloalkyl is optionally substituted with C1-C3 alkyl, because
Chappie teaches that substituent R1 is a 4 to 6-membered heterocycloalkyl which contains 1 heteroatom selected from N, O or S, wherein the 4 to 6-membered heterocycloalkyl is optionally substituted with 1 to 4 R8 which is, for example, C1-C3 alkyl, and
Chappie exemplifies R1 as a 4 to 6-membered heterocycloalkyl which contains 1 heteroatom which is O.
Thus, a person of ordinary skill in the art would have replaced the R1 which is a 4 to 6-membered heterocycloalkyl which contains 1 heteroatom which is O (in compound Example 16 Chappie, or in compounds Examples 7, 9, 10, 12 in Chappie) with R1 which is a 4 to 6-membered heterocycloalkyl which contains 1 heteroatom which is N, optionally substituted with alkyl, to arrive at a compound of the instant invention, with the expectation that such a compound that belongs to the genus of Chappie will retain therapeutic effect as LRRK2 inhibitor, effective to treat a LRRK2 associated disease.
As such, claims 1, 4, 28, 29, 30, 61-63 are rejected as prima facie obvious.
Conclusion
Claims 1, 4, 28-30, 38, 52, 61-63 are rejected.
Claim 37 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to IRINA NEAGU whose telephone number is (571)270-5908. The examiner can normally be reached Mon-Fri 8-5.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, JEFFREY S. LUNDGREN can be reached at (571)272-5541. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/IRINA NEAGU/Primary Examiner, Art Unit 1629